CD274 and neoplasm: A few potential biomarkers have been identified up to now, such as PD-L1 gene expression, microsatellite instability (MSI), mismatch repair deficiency (dMMR), POLE or JAK1/2 mutations, immune cell infiltration, IFNγ expression, tumor mutational burden (TMB) or neoantigen burden [6, 7].